



The o2h

Seven Sisters

Human Health Growth Fund - a KI EIS Fund

Raising Venture Capital to scale companies from the o2h incubator through to the clinic for the benefit of patients and investors.

Chris White
o2h Ventures

September 2025



Disclaimer

This document is personal to the recipient and has been prepared by Sunil Shah and Prashant Shah (the "Partners") solely for their use in presentations and at informational meetings relating to the proposed establishment of a venture capital fund to be run and operated by the Partners in collaboration with an FCA-authorised fund manager ("the o2h biotech growth fund") (the "Transaction") and is being delivered for information purposes only to a limited number of persons. The o2h biotech growth fund will be an alternative investment fund ("AIF") for the purposes of the European Alternative Investment Fund Managers Directive (2011/61/EU) (references to the AIFMD in this document include references to any other legislation, rules and guidance implementing the AIFMD into the national law of any member state of the European Economic Area ("EEA") as applicable) (the "AIFMD"). An alternative investment fund manager ("AIFM") authorised and regulated by the Financial Conduct Authority ("FCA") as a "small authorised UK AIFM" (in accordance with article 3(2) of the AIFMD) to manage unregulated AIFs such as the o2h biotech growth fund will be appointed to operate the fund. The manager will be required to comply with certain provisions of the AIFMD and will be subject to the supervision of the FCA and will appoint the Partners as its appointed representative to carry out certain advisory services to the fund including introducing investor and deal flow to the fund and arranging deals in investments.

This document, any oral presentation of this document by the Partners, the question-and-answer session that follows that presentation, hard copies of this document and any other document distributed at, or in connection with, that presentation (collectively the "Presentation") are for information purposes only and do not constitute or form part of, and are not intended to be construed as constituting or forming part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities or interests in the o2h biotech growth fund or securities in any other entity. No part of this Presentation, nor the fact of its distribution shall form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the o2h biotech growth fund or of any other entity. Each party to whom the Presentation is made available must make its own independent assessment of the o2h biotech growth fund after making such investigations and taking such advice as they may deem necessary.

The information and opinions provided in the Presentation are provided as of the date of the Presentation and are subject to updating, completion, revision, verification and amendment and such information may change materially. In furnishing the Presentation the Partners undertake no obligation to provide any additional information or to update the Presentation or to correct any inaccuracies in, or omissions from, the Presentation which may become apparent. No reliance may be placed for any purposes whatsoever on the information contained in the Presentation or on its completeness, accuracy or fairness.

Some statements contained in the Presentation or in documents referred to in it are or may be forward-looking statements, including, but not limited to, statements as to future operating results, work plans and potential acquisitions and contracts. The forward-looking statements include statements typically containing the words "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements are based on expectations and beliefs of the Partners at the date of the Presentation and, by their nature, are subject to a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performances and achievements of the o2h biotech growth fund to differ. The forward-looking statements are based on numerous assumptions regarding the o2h biotech growth fund's present and future business strategies and environments in which the fund may operate in the future and such assumptions may or may not prove to be correct. No statement in the Presentation is intended nor may it be construed as a profit forecast and no warranty or representation is given by the Partners in respect of such statements. Nothing in the Presentation or in documents referred to in it should be considered as a profit forecast. Past performance, particularly the performances of each Partner's personal investment portfolio, cannot be relied on as a guide to future performance of the o2h biotech growth fund.

No representation or warranty, express or implied, is given by or on behalf of the Partner or the o2h biotech growth fund or any of such person's directors, officers, advisers, agents or employees or any other person as to the accuracy or completeness of the information or opinions contained in the Presentation and, to the extent permitted by law, no liability whatsoever (in negligence or otherwise) is accepted by the Partners or the o2h biotech growth fund or any of such person's directors, officers, advisers, agents or employees or any other person for any loss, howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

The contents of the Presentation have not been approved by the Partners or to any authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. The Presentation and its contents are confidential and are made available strictly for the purposes referred to above. The Presentation may only be distributed by the Partners, and only to Relevant Persons (as defined below).

No offer of securities in the o2h biotech growth fund is being or will be made in the UK in circumstances which would require a prospectus to be prepared. This document is directed at, and is only for distribution to persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the European Prospectus Directive 2003/71/EC (or who are persons to whom it may otherwise be lawfully communicated); and in particular persons in the UK who:

(i) have professional experience in matters relating to investments falling within Article 14 of the Financial Services and Markets Act 2000 (Collective Investment Schemes)(Exemptions) Order 2001 (the "Order");

(ii) fall within Article 22 of the Order (high net worth companies, unincorporated associations etc); or


(iii) whom it can otherwise lawfully be distributed, ("Relevant Persons").

Any recipient of this Presentation who is not a Relevant Person should return it immediately, not attend any physical presentation and take no other action. The distribution, redistribution, reproduction or passing on, directly or indirectly, of this document in jurisdictions other than the UK may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any restrictions. In particular, neither this document nor any copy of it may be taken or transmitted or distributed or redistributed (directly or indirectly) in the UK without the consent of the Partners or at all in the United States, Canada, Japan or Australia. Any failure to comply with this restriction may constitute a violation of United States, Canadian, Japanese or Australian securities laws. This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities in any jurisdiction in which such offer or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. The Partners have not registered and do not intend to register any offering in the United States or to conduct any public offering of any securities in the United States.


The Partners reserve the right to change the structure of the Transaction at any time.

By attending the Presentation or by accepting this document you will be taken to have represented, warranted and undertaken (in addition to any statutory certificates or statements required to be provided, which you also undertake to provide) that: (i) you are a Relevant Person (as defined above); (ii) you have read and agree to comply with the contents of this notice; and (iii) you will not at any time have any discussion, correspondence, or contact concerning the information in the Presentation with any person without the prior written consent of the Partners.

Following on from o2h's award-winning incubator Seed Funds, we are launching our **Seven Sisters Human Health Growth Fund, to scale **7** of our most exciting companies with the clearest path to exit within **5** years, via trade sales to Big Pharma and Healthcare Enablers.**



Vision



o2h have built one of the UK's most active biotech incubators - now primed for growth

37

Biotechs in portfolio with ~£9M invested over 6 years.

7

Clinical Stage from Seed.

>£300_M

External finance leveraged


3.5x

Growth Fund target return

1

Seed to IPO
39x upon first listing
TSXV:DMT

Why biotech?



- **Aligning a passion for science/healthcare**
- **High impact**
- **Portfolio balance**

- **UK Life Sciences VC Funds have outperformed wider market (British Business Bank Report)**

- **Countercyclical – less correlated with wider economy**

- **The UK is a biotech leader and valuations here are a lot lower than the US...**

Access to UK Life Sciences Innovation

Cambridge: A Global Biotech Cluster

- Home to leading academic institutions (University of Cambridge, Babraham Institute)
- Proximity to major pharma and world-class research centres
- Rich talent pool across science, tech, and commercialisation

o2h Ventures Advantage

- Located at the heart of the Cambridge Cluster
- Direct pipeline to early-stage biotech spinouts
- Deep relationships with academics, founders, and TTOs

Capital-Efficient Innovation

- Lower operating costs vs. Boston/SF
- Attractive entry valuations
- Strong government and grant support (e.g., Innovate UK)

The UK receives


41%

of all Biotech
funding across
Europe*

* Source: BIA Finance Report 2023

Expansive biotech ecosystem built in over 20 years


The Anglo-Indian o2h Group provides o2h incubator companies with an unfair advantage.



o2h Discovery is a 600+ person Anglo-Indian Contract Research Organisation (CRO) and provides all new **o2h Ventures** investments a Kickstarter Award which would provide them a discovery team for 6 months for a nominal cost.

Incubate, Invest & Scale

We have incubated and provided the support required to bring a pool of companies ready for growth.



UK



**o2h have the capability to incubate start-ups
in our privately owned 'Mill SciTech Park'**

A long, modern laboratory with a black metal frame and a long black table. Several white robotic arms are mounted on the table, each with a clear protective dome. The room has a high ceiling with exposed pipes and a red fire alarm. A glass door is visible on the left side of the image.

India

o2h have a discovery capability in India ready to provide an option to jump start any research program

Live working relationships within Big Pharma across o2h Group

Johnson & Johnson

sanofi

 MERCK

 novo nordisk®

AstraZeneca 

AMGEN

 **Chiesi**
global rare diseases 

 **Roche** **Genentech**
A Member of the Roche Group

 **gsk**
GlaxoSmithKline

 **Takeda**

 **Boehringer
Ingelheim**

 Bristol Myers Squibb

 **NOVARTIS**
PHARMACEUTICALS

Lilly

 **Pfizer**

 **BAYER**


 **astellas**

abbvie

NXera 

The Growth Fund will invest at the most value-driving phase

Valuation at beginning of development stage



Maximizing Investment Value:

- Invest when significant risks are mitigated, yet entry price remains advantageous
- Success in early clinical phases ensures maximum value per invested pound/dollar

Well Baked Opportunities:



- o2h Ventures have been on the boards, mentoring these companies for 1-7 years.
- Early-stage companies need this time to 'cook' as they work to build the right time and find their investable proposition, developing the science.
- The Growth Fund would seek to select investments which have more than £1m in revenues or those with a clear commercial path forward.

Therapeutics

Company	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Marketed
Cybin	Completed	Completed	Completed	Completed	Completed	Completed
Exonate	Completed	Completed	Completed	Completed	Ongoing	Completed
TAY Therapeutics	Completed	Completed	Completed	Completed	Ongoing	Completed
neurocentrx	Completed	Completed	Completed	Completed	Ongoing	Completed
MONUMENT THERAPEUTICS	Completed	Completed	Completed	Completed	Ongoing	Completed
BiVictriX Therapeutics	Completed	Completed	Completed	Ongoing	Completed	Completed
CamGene Therapeutics	Completed	Completed	Completed	Ongoing	Completed	Completed
ClotProtect	Completed	Completed	Completed	Ongoing	Completed	Completed
Enedra Therapeutics	Completed	Completed	Completed	Ongoing	Completed	Completed
PENCIL BIOLOGICS	Completed	Completed	Completed	Ongoing	Completed	Completed
ALARM BIO	Completed	Completed	Completed	Ongoing	Completed	Completed
AFORD DRUG DESIGN	Completed	Completed	Completed	Ongoing	Completed	Completed
PHARMENABLE	Completed	Completed	Completed	Ongoing	Completed	Completed
REVOLVER THERAPEUTICS	Completed	Completed	Completed	Ongoing	Completed	Completed
PHOREMOST	Completed	Completed	Completed	Ongoing	Completed	Completed
STINGRAY PHARM	Completed	Completed	Completed	Ongoing	Completed	Completed
STRATOSVIR	Completed	Completed	Completed	Ongoing	Completed	Completed
SPIREA	Completed	Completed	Completed	Ongoing	Completed	Completed
alevin THERAPEUTICS	Completed	Completed	Completed	Ongoing	Completed	Completed

Platform Biotech

Proof of concept Platform Validation Pipeline Expansion Strategic Partnership Clinical Advancement Commercial Readiness Market Leadership

 **ViaNautis**
TARGETED RADIOTHERAPY



	Proof of concept	Algorithm / Platform	Pipeline Expansion	Strategic Partnership	Clinical Advancement	Commercial Readiness	Market Leadership
turbine.	Progress bar	Progress bar	Progress bar	Progress bar			
KUANO	Progress bar	Progress bar	Progress bar	Progress bar			
CardiaTec	Progress bar	Progress bar	Progress bar				
Yesynta	Progress bar	Progress bar					
AIVIVO	Progress bar	Progress bar					

AI / ML Medtech

Proof of concept Algorithm / Platform Validation Pipeline Expansion Strategic Partnership Clinical Advancement Commercial Readiness Market Leadership

xploro®

	Concept & Prototype	Preclinical / Bench Validation	Clinical Validation	Regulatory Approval	Commercial Launch	Market Expansion & Standard of Care
Heart Felt Technologies	Progress bar	Progress bar	Progress bar	Progress bar		
NEUROFENIX	Progress bar	Progress bar	Progress bar	Progress bar		
CORTIRIO	Progress bar	Progress bar				

[illegible]

Our incubated investments

Selecting our star investments for the Seven Sisters Fund

Fund 1
**Seven Sisters
2025**

ATELERIX

Exonate

ViaNautis
TARGETED NANOMEDICINES

**MONUMENT
THERAPEUTICS**

TAY
THERAPEUTICS

PHOREMOST

NEOPHORE
DYNAMIC NEOANTIGEN EVOLUTION

Qkine

neurocentrx

Heart Felt
Technologies

Fund 2
**Potential
2027**

alevin
THERAPEUTICS

AVIVO

CORTIRIO

PHARMENABLE
unlocking innovative medicines

metrion
biosciences

**OXFORD
DRUG
DESIGN**

KUANO

SPiREA

turbine.

Sansanima

Fund 3
**Incubation
2029**

CamGene
therapeutics

Stingray Bio

PENCIL
BIOSCIENCES

Hawkhill
Therapeutics

Honeybadger^{Tx}

Vesynta[®]

5 ALARMBIO

xploro[®]

Enedra Therapeutics

**The o2h
Kickstarter
Award**

*pipeline of 27+ global
o2h kickstarter award winners

Founding investors



Sunil Shah

CEO, o2h Ventures
Chief Investment Officer

- Active Biotech investor and entrepreneur for >20 years
- Board Member of Bio Industry Association, Cambridge Angels in the UK
- UKBAA Angel Investor of the year award in 2019
- OBN Special Recognition Award for his significant contribution in the Life Science
- CEO of the year award at the Cambridge Independent Science and Technology Awards
- Executive Chairman of Alevin Therapeutics & Exonate Ltd
- Non-Executive Director, Board Observer or an investor in over 30 Biotech companies
- Co-founder of o2h Discovery and o2h Co-work Labs



Prashant Shah

Founding Partner, o2h Ventures
Ecosystem Development

- Active Biotech investor and entrepreneur for >20 years
- Co-founder of o2h Discovery and o2h Co-work Labs
- An active ecosystem, community and culture builder
- Led the design and execution of the Mill SciTech Park, an award-winning boutique renovation of a disused heritage site in Hauxton, Cambridge
- Holds various board positions including the Eastern Powerhouse, Techbio/Biotech NED and chair positions including Form the Future and the Judge business school biotech alumni group

Investment Advisory Committee and experts involved

Leading scientists, biotech entrepreneurs, venture capitalists and industry executives....



Tim Sparey

**IAC, Executive Chair at
Tay Therapeutics**

A medicinal chemist with 30 years of entrepreneurial experience in large pharma and Biotechs. Built, developed and transacted in multiple therapeutics deals totalling >\$6bn



Dr Chris Torrance

IAC, Executive Chair at Phoremest Ltd

also founder of Horizon Discovery, fastest growing Biotech company in the UK



Jeff Roix

**Venture Partner, Translational
Biologist & Biotech Entrepreneur**

A scientist and biotech entrepreneur with over 15 years of experience in discovering medicines.



Dr Catherine Beech OBE

**IAC, Co-founder
and CEO at Exonate**

and prior experience as a Fund manager, has >25 years of biotech industry experience



Robert G Boyle

IAC, CEO at Sentinel Oncology

A biotech entrepreneur with >25 years' experience.



Chris Reid

**Venture Partner, Chief Investment
Officer for a Hedge Fund**

Prior to this managed a £1bn equity fund, has an experience of >18 years



Cengiz Tarhan

IAC, Head of Business at UCLB

for >30 years, has served as NED on numerous UCLB spin outs



Antonio Benedetti

**Venture Partner, Executive
Chairman at Kuano Ltd**

Pharma and automotive executive with 25+ years' leadership and a track record of launching orphan drugs and scaling global operations. Former CEO of Cycle Pharmaceuticals and Magirus GmbH


EIS Investment Opportunity

o2h Ventures are offering a limited £5m tranche of the Seven Sisters Growth Fund as a Knowledge Intensive EIS (Enterprise Investment Scheme) investment.

This will allow UK-based investors to benefit from:

- **30% Income Tax Relief** – up to £600k based on the maximum investment of £2m
- **Capital Gains Tax relief**
- **Capital Gains Deferral Relief**
- **IHT Relief via Business Relief**
- **Loss relief** should any investee companies fail

As a KI EIS fund, you will receive the tax relief in the year the fund closes (2025/26) and the relief can also be carried back to 2024/25.



For EIS investors

80% of their capital will be allocated to the 7 companies that make up the **Seven Sisters Growth Fund**.

The remaining 20% will be allocated to other o2h Ventures portfolio companies and new investments approved by our Investment Committee. All of these investments will be EIS-qualifying.

Minimum investment: **£100K**

Fees

- Same as our previous funds
- 2% initial fee (1.5% for advised clients), followed by 2% AMC, with only the first year due up front, the rest will be due upon exit (if profitable)
- 20% performance fee due once 100% of subscriptions have been returned

Fund summary & opportunities



Also from o2h Ventures...

o2h Direct: Single company SEIS investments

Invest alongside our co-founders

Our first direct investment will be a company spun-out from one of our existing investments – an oral therapy for obesity that not only reduces fat but preserves muscle mass, setting it apart from the current generation of GLP-1-based weight loss drugs.

£10k minimum investment



Thank you

Contact: chris.white@o2h.com

o2h.com/ventures